Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


Real-time Estimate Quote. Real-time Estimate CHI-X - 11/26 11:30:00 am
7785 GBX   -0.19%
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regimen
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

World stocks pause in rally, USD bounces from 3-week low

10/13/2020 | 11:36am EST

NEW YORK/LONDON, Oct 13 (Reuters) - The U.S. dollar rebounded from a three-week low on Tuesday while equity markets in Europe and the United States eased, as investors took stock of recent rallies before chasing further gains.

Analysts said Tuesday's pullback in stock markets was by no means driven by an aversion to risk, especially since investors are convinced that the U.S. government will unveil more fiscal stimulus to bolster the economy.

Still, the tempered mood in stock markets was accompanied by firmer demand for traditional safe-haven assets such as the dollar and U.S. Treasuries. A stronger dollar in turn weighed on gold prices.

The S&P 500 fell 16.8 points, or 0.46%, to 3,517.73, but still within sight its record high of 3,580.84 struck on Sept. 2. The Dow Jones Industrial Average dropped 128.4 points, or 0.45%, to 28,706.11. The Nasdaq Composite dipped 2.2 points, or 0.02%, to 11,877.63

"Markets have already priced in perfection," said Ken Polcari, chief market strategist at SlateStone Wealth LLC in Florida. "It's 'buy the rumor, sell the news.'"

European shares also struggled on Tuesday as investors looked past Chinese trade data that pointed to a buoyant recovery.

The Euro STOXX 600 lost 0.77%, ending three straight days of gains, with markets in Frankfurt, London and Paris mirroring its moves.

News that Johnson & Johnson was pausing its COVID-19 vaccine candidate clinical trials because of an unexplained illness in a study participant also gave investors a reason to take profits for now.

Investors see the quick introduction of a vaccine as key to helping economies recover. J&J's move comes after AstraZeneca paused late-stage trials of its experimental vaccine in September, also due to a participant's unexplained illness.

The sentiment in European and U.S. stock markets contrasted with earlier resilience in Asia, where shares were boosted by Chinese data that showed exports rising 9.9% in September and imports swinging to a 13.2% gain, versus a 2.1% drop in August.

The data, which suggests Chinese exporters are recovering from the pandemic's damage to overseas orders, helped Chinese blue-chip shares rise 0.33%. MSCI's broadest index of Asia-Pacific shares outside Japan, however, trimmed earlier gains and was little changed by the end of Tuesday.

In currency markets, investor demand for the dollar helped the dollar index to climb 0.416% against a basket of other currencies, putting it on track for its biggest daily percentage gain in three weeks.

Currency traders were also watching Chinese trade-related issues. Reports that Beijing has stopped taking shipments of Australian coal caused the Australian dollar to drop as much as 0.6% to $0.7165.

Government bond yields in the euro zone held near recent troughs, with hefty supply failing to dent a market bolstered by expectations for further central bank easing.

Germany's 10-year Bund yield touched -0.538%, its lowest in just over a week. Italian and Greek benchmark 10-year debt both hit record lows.

The benchmark 10-year Treasury yield was last down 4.3 basis points at 0.7322%.

Gold dropped 1.6% to $1,891.01 per ounce. (Reporting by Koh Gui Qing; Editing by Steve Orlofsky)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.67% 7748 Delayed Quote.1.85%
AUSTRALIAN DOLLAR / CANADIAN DOLLAR (AUD/CAD) 0.10% 0.95877 Delayed Quote.5.17%
AUSTRALIAN DOLLAR / JAPANESE YEN (AUD/JPY) -0.09% 76.624 Delayed Quote.0.83%
AUSTRALIAN DOLLAR / NEW ZEALAND DOLLAR (AUD/NZD) 0.00% 1.05065 Delayed Quote.0.69%
AUSTRALIAN DOLLAR / SWISS FRANC (AUD/CHF) 0.05% 0.66722 Delayed Quote.-1.36%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) 0.10% 0.73645 Delayed Quote.4.97%
BRITISH POUND / AUSTRALIAN DOLLAR (GBP/AUD) -0.02% 1.8146 Delayed Quote.-3.85%
DJ INDUSTRIAL -0.58% 29872.47 Delayed Quote.4.67%
EURO / AUSTRALIAN DOLLAR (EUR/AUD) -0.05% 1.6182 Delayed Quote.1.29%
EURO / US DOLLAR (EUR/USD) 0.07% 1.19187 Delayed Quote.6.23%
NASDAQ 100 0.60% 12152.215271 Delayed Quote.39.15%
NASDAQ COMP. 0.48% 12094.402197 Delayed Quote.34.15%
S&P 500 -0.16% 3629.65 Delayed Quote.12.35%
STOXX EUROPE 600 -0.12% 391.63 Delayed Quote.-5.71%
STOXX EUROPE 600 NR -0.10% 862.42 Delayed Quote.-3.81%
All news about ASTRAZENECA PLC
05:16pNEWS HIGHLIGHTS : Top Company News of the Day
03:31pASTRAZENECA : says working with regulators on best approach to lower dose regime..
03:16pNEWS HIGHLIGHTS : Top Company News of the Day
02:11pRussia's Sputnik V developers call on AstraZeneca to try combining vaccines
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
12:51pASTRAZENECA : Top UK scientific adviser says AstraZeneca vaccine works
11:54aAstraZeneca CEO expects to run new global trial of COVID-19 vaccine - Bloombe..
11:16aNEWS HIGHLIGHTS : Top Company News of the Day
10:58aANALYSIS : Questions over AstraZeneca's COVID-19 vaccine data risk delaying appr..
10:06aWhy the Oxford Astrazeneca Vaccine Is Now a Global Gamechanger
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 46,6x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,48 $
Last Close Price 103,46 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-4.41%282 585
PFIZER INC.-1.59%203 048
NOVARTIS AG-11.88%202 620
MERCK & CO., INC.-11.97%202 555